Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Non-Current Deffered Revenue (2016 - 2024)

Historic Non-Current Deffered Revenue for Ernexa Therapeutics (ERNA) over the last 13 years, with Q2 2024 value amounting to $298000.0.

  • Ernexa Therapeutics' Non-Current Deffered Revenue rose 1920.0% to $298000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $298000.0, marking a year-over-year increase of 1920.0%. This contributed to the annual value of $392000.0 for FY2023, which is N/A changed from last year.
  • Ernexa Therapeutics' Non-Current Deffered Revenue amounted to $298000.0 in Q2 2024, which was up 1920.0% from $345000.0 recorded in Q1 2024.
  • In the past 5 years, Ernexa Therapeutics' Non-Current Deffered Revenue ranged from a high of $392000.0 in Q4 2023 and a low of $1000.0 during Q1 2020
  • Its 3-year average for Non-Current Deffered Revenue is $223500.0, with a median of $250000.0 in 2023.
  • In the last 5 years, Ernexa Therapeutics' Non-Current Deffered Revenue plummeted by 9565.22% in 2020 and then skyrocketed by 3800.0% in 2024.
  • Over the past 3 years, Ernexa Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $2000.0 in 2020, then skyrocketed by 19500.0% to $392000.0 in 2023, then fell by 23.98% to $298000.0 in 2024.
  • Its Non-Current Deffered Revenue stands at $298000.0 for Q2 2024, versus $345000.0 for Q1 2024 and $392000.0 for Q4 2023.